Prognosis for Metastatic Triple Negative Breast Cancer

Introduction to Prognosis

Metastatic triple-negative breast cancer (TNBC) carries a poorer prognosis compared to other breast cancer subtypes, with patients experiencing peak risk of recurrence within 3 years of diagnosis and increased mortality rates for 5 years after diagnosis 1, 2, 3

African-American race/ethnicity (TNBC is three times more common in women of African descent) 2, 4, 5
Younger age at diagnosis 1, 2, 3
More advanced disease stage at presentation 1, 2, 3
Higher tumor grade and high mitotic indices 1, 2, 3
Non-Hispanic black women with late-stage TNBC have particularly poor outcomes, with a 5-year relative survival of only 14% 4

TNBC represents 10-20% of all invasive breast cancers 1, 2, 3
TNBC is characterized by absence of estrogen receptor (ER), progesterone receptor (PR), and no overexpression of human epidermal growth factor receptor 2 (HER2) 1, 2, 3
TNBC is associated with BRCA1 mutations and family history of breast cancer 1, 2, 3
Approximately 75% of TNBCs are basal-like breast cancers 4, 6

Patients with metastatic TNBC should be tested for actionable biomarkers that may improve prognosis, including PD-L1 status (for immunotherapy eligibility) 7
Patients with metastatic TNBC should be tested for germline BRCA1/2 mutation status (for PARP inhibitor eligibility) 7
PIK3CA mutations may also be relevant in some cases 7

TNBC has a higher propensity for visceral metastases compared to bone metastases 7
There has been an increase in liver and central nervous system metastases over time 7
The pattern of metastatic spread can impact prognosis, with CNS involvement generally associated with poorer outcomes 7

The National Comprehensive Cancer Network recommends that BRCA1-related breast cancers are characteristically triple-negative, with studies showing BRCA1 mutations in 7-16% of all TNBC patients 8, 9, 10
Among early-onset TNBC (diagnosed before age 40), the incidence of BRCA1 mutations reaches 36% 8, 10
The median age of diagnosis for BRCA1 mutation carriers with TNBC is 39 years 8, 9, 10
BRCA1/2 mutation carriers with TNBC showed better 2-year overall survival (95% vs 91%, HR 0.59, 95% CI 0.35-0.99, P=0.047) compared to non-carriers 8, 9, 10
Carriers of BRCA1 mutations diagnosed before age 50 had worse overall survival (HR 1.28, 95% CI 1.05-1.57, P=0.01) compared to non-carriers 11

BRCA2-related tumors more closely resemble sporadic tumors and are typically hormone receptor-positive rather than triple-negative 12
Among BRCA2 carriers with ER-positive tumors, the 20-year survival rate was only 62.2%, compared to 83.7% for those with ER-negative tumors (P=0.03 in patients younger than 50) 9, 10
ER-positive disease in BRCA2 carriers was associated with increased mortality risk (HR 1.94, 95% CI 1.22-3.07, P=0.005) 9, 10